Literature DB >> 26166019

Expression of coinhibitory PD-L1 on CD4⁺CD25⁺FOXP3⁺ regulatory T cells is elevated in patients with acute coronary syndrome.

Si-Hui Li1, Wei-Jun Chen, Min Yan, Yan-Wen Shu, Yu-Hua Liao.   

Abstract

OBJECTIVE: Coronary heart disease (CHD) is associated with high morbidity and mortality worldwide. CD4⁺CD25⁺FOXP3⁺ regulatory T cells (Tregs) play a role in the modulation of vascular inflammation. The negatively costimulatory molecule programmed cell death ligand 1 (PD-L1) exerts a prominent effect on the adjustment of immune responses. We investigated the relationship between the expression of PD-L1 on peripheral blood Tregs and the severity of CHD. METHODS AND
RESULTS: Human peripheral blood was collected from 59 patients with CHD and 11 healthy volunteers. The expression of PD-L1 on peripheral blood Tregs was detected by flow cytometry, and the production of interleukin 2 (IL-2), IL-4, IL-10, and transforming growth factor β1 in plasma was determined using enzyme-linked immunosorbent assay. The subgroup of patients with acute coronary syndrome (ACS), which includes unstable angina pectoris, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction, showed a significant reduction of FOXP3 and PD-L1 expression on Tregs compared with the subgroup of patients with chronic coronary artery disease, comprising stable angina pectoris, silent myocardial ischemia, and ischemic heart failure, and the control group. Moreover, the ACS group showed significantly increased production of IL-2, and decreased production of IL-4, IL-10, and transforming growth factor β1, compared with the coronary artery disease and control groups.
CONCLUSION: Expression of the coinhibitory molecule PD-L1 on peripheral blood Tregs is correlated negatively with the severity of CHD and could serve as a novel indicator of ACS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26166019     DOI: 10.1097/MCA.0000000000000282

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  6 in total

Review 1.  Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-Art Review.

Authors:  Jacqueline T Vuong; Ashley F Stein-Merlob; Arash Nayeri; Tamer Sallam; Tomas G Neilan; Eric H Yang
Journal:  J Am Coll Cardiol       Date:  2022-02-15       Impact factor: 24.094

Review 2.  Role of cytokines and inflammation in heart function during health and disease.

Authors:  Monika Bartekova; Jana Radosinska; Marek Jelemensky; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 3.  Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.

Authors:  Pilar Martín; Rafael Blanco-Domínguez; Raquel Sánchez-Díaz
Journal:  Cell Mol Immunol       Date:  2020-11-24       Impact factor: 11.530

4.  Serum Cytokine Profile in Relation to the Severity of Coronary Artery Disease.

Authors:  Xiaoyan Min; Miao Lu; Su Tu; Xiangming Wang; Chuanwei Zhou; Sen Wang; Sisi Pang; Jin Qian; Yiyue Ge; Yan Guo; Di Xu; Kejiang Cao
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

5.  Association between the level of CD4+ T lymphocyte microRNA-155 and coronary artery disease in patients with unstable angina pectoris.

Authors:  Zi-Liang Ye; Hai-Li Lu; Qiang Su; Lang Li
Journal:  J Geriatr Cardiol       Date:  2018-10       Impact factor: 3.327

6.  Early Onset Acute Coronary Artery Occlusion After Pembrolizumab in Advanced Non-Small Cell Lung Cancer: A Case Report.

Authors:  Yuan Cheng; Ligong Nie; Wei Ma; Bo Zheng
Journal:  Cardiovasc Toxicol       Date:  2021-05-27       Impact factor: 3.231

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.